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Introduction
P. aeruginosa is an opportunistic Gram-negative pathogen 
accounting for significant morbidity and mortality worldwide and is 
the second most frequent cause of healthcare- or ventilator-associated 
pneumonia [1]. Multidrug resistance (MDR) is defined as resistance 
to 3 or more antibiotics and the incidence of MDR in P. aeruginosa is 
increasing [2]. As a consequence, P. aeruginosa is likely to pose a major 
therapeutic challenge in future [1]. 
Membrane-associated efflux-pumps belonging to the resistance-
nodulation-division (RND) family actively export antibiotics and as a 
consequence are major contributors to P. aeruginosa antibiotic resistance 
[1]. Of the 12-member RND family, MexAB-OprM is considered to 
be the most important efflux-pump mediating antibiotic resistance 
in P. aeruginosa because it transports a broad range of antibiotics [1]. 
Mutations in efflux-pump regulatory genes can result in efflux-pump 
overexpression that confers a MDR phenotype [3] and are commonly 
identified in clinical isolates, for example, mutations in nalB result in 
over-expression of MexAB-OprM, and contribute to reduced clinical 
efficacy of some antibiotics [4]. Treatments that combine efflux-pump 
inhibitors (EPIs) with antibiotics that are normally ineffective due to 
efflux could result in restoration of the normal clinical efficacy of the 
drug [5].
Curcumin (CUR) is a phenolic compound derived from the rhizomes 
of the plant Curcuma longa that is cultivated in India and Asia and 
is a constituent of the food ingredient turmeric. The compound has 
been studied extensively and has been shown to possess significant 
antimicrobial, anti-inflammatory, anti-cancer and anti-oxidant 
properties (reviewed in [6,7]). The antibacterial action of CUR has been 
attributed to inhibition of polymerisation of the essential prokaryotic 
cell division protein FtsZ thus preventing cytokinesis [8]. Furthermore, 
CUR reverses the drug resistance of cancer cells by modulating the 
activity of multi-drug efflux pumps [9], competitively inhibits Candida 
albicans ATP-binding cassette transporters and displayed synergistic 
inhibition of yeast strains expressing these efflux-pumps in combination 
with selected azoles [10], and finally, also inhibits the NorA efflux-
pump of Staphylococcus aureus resulting in an 8-fold reduction in the 
MIC of ciprofloxacin [11].
Evidence has been presented that CUR and the arylpiperazine, 
1-(1-naphthylmethyl)-piperazine (NMP) could also be acting as EPIs 
in vitro [12,13] versus Gram-negative bacteria. CUR reduced the MIC 
of several antibiotics against MDR isolates of P. aeruginosa and this 
was attributed to efflux-pump inhibition. Similarly, NMP was shown 
to reverse MDR in Escherichia coli strains over-expressing RND efflux-
pumps by enhancing susceptibility to antibiotics and increasing their 
intracellular concentration. 
Employing a P. aeruginosa nalB-type strain that possesses 
mutation(s) in the MexR repressor that results in overexpression of 
the MexAB-OprM efflux pump [3,14], this study assessed the efficacy 
of combinations of antibiotics with CUR and NMP using a Galleria 
mellonella in vivo infection model to determine if these combinations 
could provide therapeutic benefit versus infections with a P. aeruginosa 
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Abstract
Objective: The aim of this study was to determine if the plant phenolic curcumin (CUR) and the arylpiperazine 
1-(1-naphthylmethyl)-piperazine (NMP) could restore antibiotic efficacy versus MDR P. aeruginosa infection. 
Methods: The MICs of piperacillin, meropenem and levofloxacin in the presence or absence of CUR or NMP 
against a MDR strain that over-expresses the MexAB-OprM efflux-pump and the isogenic parent strain were compared. 
The efficacy of the same combination treatments was also tested in a Galleria mellonella in vivo infection model and 
larval survival and bacterial burden compared. 
Results: In vitro, CUR restored the activity of piperacillin, meropenem and levofloxacin versus the MDR strain of P. 
aeruginosa only weakly. There was no evidence in vitro of a similar effect with NMP. In vivo, treatment of G. mellonella 
larvae infected with the MDR strain with a combination of NMP or CUR plus levofloxacin, and piperacillin plus CUR, 
resulted in enhanced therapeutic benefit compared to the monotherapies. When compared with monotherapies, the 
enhanced efficacy of the combination treatments correlated with reduced bacterial burden. 
Conclusion: CUR and NMP restored the efficacy of antibiotic therapy in vivo versus MDR P. aeruginosa infection. 
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strain possessing an efflux-pump-mediated MDR phenotype.
Materials and Methods
Bacteria and growth media 
 The strains of P. aeruginosa used were PAO1 (PAM1020) - the 
isogenic parent, and PAM1032 - harbouring a mutation in nalB that 
results in over-expression of the RND efflux-pump MexAB-OprM 
[14]. The strains were a kind gift of Dr. Olga Lomovskaya, Rempex 
Pharmaceuticals, USA. Strains were cultured overnight in Mueller-
Hinton Broth (MHB; Merck, Darmstadt, Germany) at 37°C with 
shaking to prepare inocula for drug susceptibility testing in vitro and 
efficacy testing in vivo. 
Antibiotics and G. mellonella larvae. All antibiotics, Pseudomonas 
Isolation Agar (PIA), curcumin (CUR) (≥65% HPLC) and arylpiperazine 
1-(1-naphthylmethyl)-piperazine (NMP) were purchased from Sigma-
Aldrich Ltd (Dorset, UK). Antibiotic stock solutions were made in 
sterile deionised water and CUR or NMP in DMSO. Sub-stocks of all 
drugs for use in experiments were made in sterile deionised water. G. 
mellonella larvae were purchased from UK Waxworms Ltd (Sheffield, 
UK).
Antibiotic, CUR or NMP susceptibility in vitro. This was performed 
as previously described [15]. Briefly, the MIC of antibiotics, CUR or 
NMP, or combinations of CUR or NMP with antibiotics was carried 
out via doubling dilution of each drug in MHB and subsequent 
inoculation with 1.0 × 106 cfu/mL of P. aeruginosa PAM1020 or 1032. 
For combination MICs, doubling dilutions of each antibiotic was 
followed by addition of CUR or NMP at three concentrations less 
than the MIC values for each compound. CUR and NMP were tested 
in combination with piperacillin (PIP), meropenem (MEM) and 
levofloxacin (LVX). Microplates were incubated at 37°C and the MIC 
was defined as the concentration present in the first optically clear well 
after 24 h. Each experiment was performed in triplicate. Fractional 
inhibitory concentration index (FICI) values were calculated for 
each combination tested [16], and synergy was defined as FICI ≤ 0.5. 
The FICI was calculated as follows: FIC of drug A = MIC drug A in 
combination/MIC of drug A alone; FIC of drug B = MIC of drug B in 
combination/MIC of drug B alone; thus, FICI = FIC of drug A + FIC 
of drug B. 
G. mellonella model of P. aeruginosa infection. This was performed 
exactly as previously described [15]. Larvae were infected with an 
inoculum of 2.5 × 103 cfu/mL of P. aeruginosa PAM1020 or 1032. Single 
doses of PIP (10, 25 and 100 mg/kg), MEM (0.1, 0.25 and 0.5 mg/kg) 
and LVX (0.2, 1 and 5 mg/kg) were administered. A dose of 100 mg/
kg of CUR or 200 mg/kg of NMP was used in combination with PIP, 
MEM or LVX as pilot studies revealed that these doses resulted in 
optimal results (data not shown). Single doses of the antibiotics, CUR 
or NMP, or combinations, were administered 2 h post-infection (p.i). 
For triple doses of single drugs, or dual drug combinations, the second 
and third doses were administered 4 and 6 h p.i respectively. Triple 
doses consisted of 1 and 5 mg/kg of LVX or 10 and 100 mg/kg of PIP 
for PAM1020 and PAM1032 respectively. For both strains, the dose of 
CUR or NMP administered alone or in combination with antibiotics 
remained the same at 100 mg/kg or 200 mg/kg respectively.
Experimental groups contained 15 larvae and were repeated 
twice using larvae from different batches. Data from these replicate 
experiments were pooled to give n=30. Survival data were plotted using 
the Kaplan-Meier method and comparisons made between groups 
using the log rank test. In all comparisons to the negative control it was 
the uninfected control (rather than the unmanipulated control) that 
was used. In all tests P ≤ 0.05 was considered significant and Holm’s 
correction was always applied to account for multiple comparisons [17].
For haemolymph burden, groups of 30 larvae were infected with 
2.5 × 103 cfu/mL of P. aeruginosa PAM1032. Single drug or dual 
combinations were administered three times at 2, 4 and 6 h p.i. The 
larvae were incubated in Petri dishes at 37°C. At 24 h intervals, five 
larvae were selected at random from each treatment group and tested 
for haemolymph burden exactly as previously described [15].
Results
In vitro, combination of CUR restores the antibiotic susceptibility of 
a P. aeruginosa strain that overexpresses the efflux-pump MexAB-OprM. 
In vitro susceptibility of the parent strain (PAM1020) and the 
strain that overexpresses MexAB-OprM (PAM1032) to PIP, MEM 
and LVX, with or without the presence of CUR or NMP, is shown 
in Table 1. Only these antibiotics were tested because previous work 
with a broad range of antibiotics revealed that the greatest decreases in 
susceptibility occurring in the nalB-type strain compared to the parent 
strain (attributed to overexpression of MexAB-OprM) occurred with 
these drugs [15]. Confirming earlier work [15], nalB-dependent over-
expression of MexAB-OprM conferred resistance to PIP, MEM and 
LVX compared to the isogenic parent (PAM1020).
NMP alone had no significant inhibitory activity against either of 
the P. aeruginosa strains tested: the MIC for both PAM1020 and 1032 
was > 128 mg/L. CUR alone had weak inhibitory activity with a MIC of 
64 mg/L for both strains. For the parent strain (PAM1020), combination 
of NMP with any of the three antibiotics tested did not reduce their MIC 
values but combination with CUR reduced the antibiotic MICs slightly. 
However, the calculated FICI values for all of these combinations 
versus PAM1020 indicated no significant synergistic inhibition (>0.5). 
A similar pattern of results were observed for the combination of NMP 
or CUR with the same antibiotics versus the MDR strain (PAM1032). 
With this strain, combination of CUR with each of the three antibiotics 
did reduce the antibiotic MIC values to a greater extent than with the 
parent strain and this was reflected in lower FICI values. Nevertheless, 
the FICI values were still greater than 0.5 indicating that the interaction 
between CUR and the antibiotics was not strongly synergistic.
The effect of combination of CUR with PIP, MEM and LVX on the 
viability of PAM1020 and PAM1032 after 24 h exposure is shown in 
Table 2. Data for NMP is not shown because no differences in viability 
were detected for either strain for any of the drug combinations tested. 
Supporting the data in Table 1, combination of CUR with the antibiotics 
did reduce the viability of the MDR strain, PAM1032, by almost 1 log10 
cfu/mL compared to the individual treatments. The same combinations 
had little additional effect over and above the individual treatments on 
the viability of the parent strain PAM1020. 
In conclusion, CUR had a weak restorative effect on the activity of 
PIP, MEM and LVX versus a P. aeruginosa strain with an efflux-pump-
mediated MDR phenotype in vitro. There was no evidence in vitro of a 
similar effect with NMP. 
In G. mellonella larvae, combination of CUR or NMP with antibiotics 
results in enhanced efficacy versus MDR P. aeruginosa infection.
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Strain Treatment Concentration Inoculum Untreated control Treatment ( ± SD) Log reduction
  (mg/L)
 
6.71 ± 0.137
 
 
9.85 ± 0.008
 
  
PAM1020
PIP 0.5 9.72 ± 0.02 0.13
MEM 0.0625 9.69 ± 0.01 0.16
LVX 0.125 9.69 ± 0.04 0.16
CUR 32 9.69 ± 0.05 0.16
PIP + CUR 0.5 + 32 9.63 ± 0.05 0.22
MEM + CUR 0.0625 + 32 9.67 ± 0.02 0.18
LVX + CUR 0.25 + 32 9.63 ± 0.04 0.22
PAM1032
PIP 4
6.72 ± 0.14
 
9.69 ± 0.029
 
9.83 ± 0.02 -0.14
MEM 1 9.69 ± 0.12 0
LVX 2 9.70 ± 0.13 -0.01
CUR 32 9.85 ± 0.12 -0.16
PIP + CUR 4 + 32 8.83 ± 0.02 0.86
MEM + CUR 1 + 32 8.82 ± 0.06 0.87
LVX + CUR 2 + 32 8.79 ± 0.07 0.9
Table 2: The effect of dual combinations of antibiotics with curcumin on the viability of P. aeruginosa PAM1020 and PAM1032 in vitro. Viability was determined in 96-well 
microplates after 24 h exposure to the antibiotics in MHB at 37°C. Data shown is the mean and standard deviation.
The same combinations were then investigated for in vivo efficacy 
in G. mellonella larvae. Importantly, neither CUR nor NMP, when 
administered alone at the highest doses tested, 100 and 200 mg/kg 
respectively, had any toxic effect on the larvae (data not shown). Initial 
experiments compared the efficacy of a single dose administered 2 h 
post-infection (p.i) of the antibiotics alone (PIP, MEM or LVX), the 
EPIs alone (CUR or NMP) and each antibiotic in combination with 
CUR or NMP. Treatment with the combinations NMP + PIP, CUR + 
MEM and NMP + MEM conferred no therapeutic benefit compared 
to antibiotic monotherapy alone. The combinations of NMP + LVX 
and CUR + PIP or LVX resulted in a small increase in survival after 
96 h, compared to PBS or monotherapies, of G. mellonella larvae 
infected with the MDR strain of P. aeruginosa (PAM1032) (data not 
shown). None of the combination treatments conferred any additional 
therapeutic benefit over monotherapies upon larvae infected with the 
parent strain PAM1020 (data not shown).
The three combination treatments that demonstrated some 
enhanced therapeutic benefit after a single dose were then tested using a 
triple dose administered 2, 4 and 6 h p.i (Figure 1). A triple dose of LVX 
+ NMP resulted in a significant increase in survival compared to triple 
Table 1: Minimum inhibitory concentrations (MICs) of three antibiotics in the presence or absence of NMP or CUR against Pseudomonas aeruginosa PAM1020 and 1032. 
Each experiment was completed at least in duplicate.
Strain Drug
Drug MIC (mg/L) with FICI2
No EPI NMP1 CUR1 Drug + NMP Drug + CUR
PIP 4-8 4 2 1.78 1.28
PAM1020 MEM 0.5-1 1 0.5 2.78 1.78
LVX 0.5 0.5 0.25 1.78 1.28
PIP 16-32 16 2 1.78 0.96
PAM1032 MEM 4 4 0.125 1.78 0.81
LVX 2 2 0.03 1.78 0.79
1The MIC versus both PAM1020 and 1032 was >128 mg/L for NMP and 64 mg/L for CUR. The concentration of NMP or CUR added to each well was selected to be 
lower than the MIC for each strain: NMP (1,10 or 100 mg/L) and CUR (0.5, 5 or 50mg/L) and the FICI value was calculated using the highest concentration tested.
2Fractional inhibitory concentration index (FIC index) where synergistic (≤ 0.5), non-synergistic (> 0.5 – ≤2.0) and antagonistic (>4). An actual MIC was not determined 
for NMP so the highest value tested was used in the FICI calculation to provide a conservative estimate of the FICI value.
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Figure  1: Effect of treatment with combinations of (a) LVX + NMP, (b) PIP + CUR and (c) LVX + CUR on survival of G. mellonella larvae infected 
with P. aeruginosa PAM 1020 or PAM 1032. All larvae were inoculated with 2.5 × 103 cfu/mL P. aeruginosa and treated with each drug individual-
ly or in combination with three doses at 2, 4 and 6 h p.i. Treatments consisted of PBS, NMP (200 mg/kg), CUR (100 mg/kg), LVX (PAM1020 1 
mg/kg; PAM1032 5 mg/kg) and PIP (PAM1020 10 mg/kg; PAM1032 100 mg/kg) alone, or combinations of the antibiotics with CUR or NMP 
administered at the same dosages. Larvae were incubated at 37°C for 96 h and survival recorded every 24 h. * indicates a combination treatment 
group with significantly enhanced survival compared to any of the constituent monotherapies (P < 0.05, log-rank test with Holm correction for 
multiple comparisons). n=30 (pooled from duplicate experiments).
Figure  1: Effect of treatment with combinations of (a) LVX + NMP, (b) PIP + CUR and (c) LVX + CUR on survival of G. mellonella larvae infected with P. aeruginosa 
PAM1020 or PAM1032. All larvae were inoculated with 2.5 × 103 cfu/mL . aeruginosa and treated with each drug individually or i  combination with three doses 
at 2, 4 and 6 h p.i. Treatments consisted of PBS, NMP (200 mg/kg), CUR (100 mg/kg), LVX (PAM1020 1 m /kg; PAM1032 5 mg/kg) an  PIP (PAM1020 10 mg/kg; 
PAM1032 100 mg/kg) alone, or combinati ns of the antibiotics with CUR or NMP administered at the sa e dosages. Larvae were incubated at 37°C for 96 h and 
survival recorded every 24 h. * indicates a combination treatment group with significantly enhanced survival compared to any of the constituent monotherapies (P 
< 0.05, log-rank test with Holm correction for multiple comparisons). n=30 (pooled from duplicate experiments).
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following three doses of either NMP (Figure 2a) or CUR (Figure 2b) 
alone increased from below the level of detection (≤2 log10 cfu/mL) 5 
h post-infection to greater than 8 log10 cfu/mL after 24 h at 37°C. This 
rapid proliferation of P. aeruginosa seen 24 h after infection correlated 
with death of the larval population (Figure 1). Treatment with three 
doses of LVX or PIP alone did retard bacterial growth over 96 h which 
in both cases was reflected by some larval survival. Notably, treatment 
with triple doses of LVX + NMP or PIP + CUR reduced larval burden 
compared to the monotherapies reflecting the higher levels of larval 
survival observed (Figure 1). 
In summary, combination of antibiotics with CUR or NMP can 
restore antibiotic efficacy in vivo versus infections with a strain of P. 
aeruginosa possessing an efflux-pump-mediated MDR phenotype and 
this enhanced efficacy of the combination treatments correlates with 
reduced larval burden of the infecting pathogen. Importantly, this 
therapeutic benefit was not detected in comparative in vitro studies.
doses of any of the monotherapies over 96 h (P ≤ 0.05). This enhanced 
therapeutic benefit of the combination treatment was observed for both 
the parent strain (PAM1020) and the MDR strain (PAM1032). Notably, 
this result contradicts the results seen in vitro where the combination of 
LVX with NMP was not observed to be synergistic versus either strain 
(Table 1). 
Triple doses of PIP + CUR and LVX + CUR also induced 
significantly enhanced survival over their constituent monotherapies (P 
≤ 0.05) but this was only observed against infection caused by the MDR 
strain. In contrast to the data obtained with NMP, the enhancement of 
antibiotic efficacy observed with CUR was partly supported by the in 
vitro data that showed CUR increased susceptibility of PAM1032 to all 
three antibiotics tested (Table 1). 
The effect of triple doses of the two most efficacious combination 
therapies LVX + NMP and PIP + CUR on the larval burden of the MDR 
strain (PAM1032) was compared (Figure 2a and 2b). Larval burden 
 
Figure 2: Effect of treatment with combinations of (a) LVX + NMP and (b) PIP + CUR on larval burden of P. aeruginosa PAM1032.  All larvae were inoculated 
with 2.5x103 cfu/mL P. aeruginosa and treated with three doses of each individual drug or combinations at 2, 4 and 6 h p.i. Treatments consisted of PBS, LVX (5 
mg/kg), PIP (100 mg/kg), NMP (200 mg/kg) or CUR (100 mg/kg) alone, or combinations of the antibiotics with CUR or NMP administered at the same dosages. 
Larvae were incubated at 37°C for 96 h and the burden of P. aeruginosa determined from 5 individual larvae every 24 h. For clarity, data for treatment with PBS 
alone is not shown because the data obtained was similar to that obtained for NMP or CUR treatment alone. * indicates a significant difference in larval burden 
between groups treated with the combination therapies compared to the constituent monotherapies; n=5 (P<0.05, unpaired t-test). The black bar represents the 
median value of larval burden per group.
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Discussion
Many antibiotic-resistant clinical isolates of P. aeruginosa that 
prove difficult to treat overexpress efflux-pumps [3]. The use of EPIs in 
combination treatments with existing antibiotics have been proposed 
as a potential solution to the lack of new antibiotics suitable for treating 
MDR P. aeruginosa infections that would restore the efficacy of drugs 
normally rendered ineffective by efflux-pumps [5].
CUR possesses antimicrobial properties but has only weak activity 
versus P. aeruginosa [12]. This work confirmed this weak inhibitory ac-
tivity. CUR attenuated virulence of P. aeruginosa in a Caenorhabditis el-
egans infection model which was attributed to down-regulation of quo-
rum-sensing, virulence factor production and biofilm formation [18]. 
Notably, a recent study showed that CUR reduced the antibiotic MIC 
of MDR clinical isolates of P. aeruginosa in vitro and this was attributed 
to efflux-pump inhibition despite no specific evidence for this being 
presented [12]. Supporting this, the in vitro data presented here showed 
that CUR reversed the antibiotic resistance of an MDR P. aeruginosa 
isolate but only weakly. In vitro, CUR had a greater inhibitory effect in 
combination with the antibiotics on PAM1032 than the parent strain 
PAM1020. Thus, it cannot be discounted that this enhanced inhibitory 
effect of CUR with antibiotics in the strain with the nalB background 
could be due to other effects of this mutation that are independent of 
the over-expression of the MexAB-OprM efflux pump.
Bohnert et al. [13] reported that the arylpiperazine NMP was able 
to reverse E. coli antibiotic resistance in vitro due to efflux-pump inhibi-
tion. Subsequently, NMP was shown to act via competitive inhibition of 
efflux-pumps [19]. However, in this work NMP did not reverse the ef-
flux-pump mediated resistance of P. aeruginosa to PIP, MEM or LVX in 
vitro. Supporting this, a recent study revealed that NMP did not reduce 
the ciprofloxacin MIC of a series of ciprofloxacin-resistant P. aerugi-
nosa clinical isolates in contrast to another EPI, phenylalanine-argi-
nine-β-naphthylamide [20].
Using G. mellonella larvae, the present study has shown that com-
binations of NMP with LVX and CUR with PIP or LVX conferred sig-
nificant therapeutic benefit compared to the individual monotherapies 
in vivo to larvae infected with a MDR strain of P. aeruginosa. In each 
example, CUR or NMP was able to restore the efficacy of each of the 
administered antibiotics to varying degrees. These results support the 
aforementioned studies showing that the co-administration of antibiot-
ics with CUR or NMP reverses MDR phenotypes in vitro but does not 
prove that this is due to efflux-pump inhibition.
Notably, there were discrepancies between the results observed in 
vitro with those in vivo – for example, NMP + LVX, the most potent 
combination in vivo was not synergistic in vitro, and CUR + MEM had 
one of the lowest FICI scores in vitro but conferred no therapeutic ben-
efit in vivo. Similar discrepancies were also seen in a previous study that 
employed the G. mellonella infection model [15]. There are many ex-
amples where combinations of antibiotics are shown to have enhanced 
activity in vitro but offer no therapeutic benefit when tested in vivo (re-
viewed in [21]). Thus, screening for novel antibiotic treatments in vitro 
is not a good predictor of in vivo efficacy and instead should be per-
formed in rapid, tractable in vivo infection models such as G. melonella 
larvae to ensure a greater chance of success when these treatments are 
tested in subsequent mammalian infection models. 
Both CUR and NMP have poor aqueous solubility which is not ideal 
for a prospective drug candidate. However, in an attempt to improve 
oral bioavailability of CUR researchers have investigated coupling 
the compound to nanocarriers. Thus, curcumin-loaded poly lactide-
co-glycolide and curcumin nanoparticles had superior bioactivity 
and bioavailability in addition to enhanced cellular uptake compared 
to curcumin alone [22]. In addition, encapsulation of curcumin with 
gelatin or starch improved the solubility and stability of the compound 
whilst retaining antimicrobial activity [23]. 
Future work will be required to confirm the enhanced efficacy of 
these combination treatments in mammalian infection models and to 
determine if either CUR or NMP has potential for clinical application. 
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